bastijn

InnoSer expands its preclinical neuroscience expertise with the acquisition of Sylics

This strategic acquisition substantially expands InnoSer’s preclinical neurology portfolio, adding in vivo rodent models for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis as well as key rare ...

Back to

Stay up-to-date

Sign up for our newsletter and stay up-to-date with the latest news and publications

Pellentesque varius massa vitae aliquet tristique.

Pellentesque varius massa vitae aliquet tristique.

Pellentesque varius massa vitae aliquet tristique.

Please enter your name.
Please enter a message.